Announcements


April 2017
2017 April, 25
Communique Annual General Meeting April 2017
Read more
2017 April, 25
Interview with Oncology Venture Sweden AB in Berlingske Tidende
Read more
2017 April, 21
MPI increases its share capital with nominal DKK 6,190 as a result of exercise of 123,800 warrants
Read more
2017 April, 12
MPI - Epirubicin-DRP data for Breast Cancer accepted for presentation at ASCO
Read more
2017 April, 10
CORRECTION: MPI - Notice to convene Ordinary Annual General Meeting CORRECTION
Read more
2017 April, 10
MPI - Notice to convene Ordinary Annual General Meeting CORRECTION
Read more
2017 April, 10
MPI - Notice to convene ordinary Annual General Meeting
Read more
March 2017
2017 March, 31
MPI publishes Annual Report for 2016
Read more
2017 March, 28
MPI's spinout Oncology Venture in-licenses 2BBB's Phase 2 lead product '2B3-101' for 2X Oncology's pipeline
Read more
2017 March, 24
MPI's spinout Oncology Venture to evaluate Eisai oncology drug for in-license to 2X Oncology Inc.
Read more
2017 March, 22
Interview with Medical Prognosis Institute and Oncology Venture in Millionærklubben
Read more
2017 March, 20
New date for publication of the Annual Report for 2016
Read more
2017 March, 13
Meet Medical Prognosis Institute at 'Investordagen' in Copenhagen March 21st 2017 - get your free ticket here:
Read more
2017 March, 08
Exercise of warrants in Oncology Venture Sweden AB
Read more
February 2017
2017 February, 24
MPI - Communiqué from the EGM of MPI 24 February 2017
Read more
2017 February, 22
MPI - Communiqué from the Extraordinary Shareholders' Meeting of MPI
Read more
2017 February, 07
MPI - Notice to convene extraordinary general meeting - warrants
Read more
2017 February, 07
MPI - Notice to convene extraordinary general meeting
Read more
January 2017
2017 January, 24
DRP successfully predicts effect of 4 Breast Cancer drugs for Personalized Medicine
Read more
2017 January, 19
MPI's spinout Oncology Venture granted EUROSTARS funding for PoC of LiPlaCis
Read more
2017 January, 09
MPI's DRP for Oncology Ventures lead product LiPlaCis registered for CE-marking in EU
Read more
2017 January, 05
MPI increases its share capital with nominal DKK 6,337 as a result of exercise of 126,740 warrants
Read more
December 2016
2016 December, 30
MPI and OV enters exclusivity and ownership agreements of SPVs - financing secured for the first two SPVs
Read more
November 2016
2016 November, 03
MPI increases its capital with nominal DKK 2,000 as a result of exercise of 40,000 warrants
Read more
October 2016
2016 October, 28
MPI - Scientific publication in the Danish Journal Best Practice describes APO010 and its DRP
Read more
2016 October, 10
Poster on Immuno Oncology APO010 sensitivity for Multiple Myeloma presented at ESMO
Read more
2016 October, 08
Poster on Successful DRP prediction of cisplatin and vinorelbine in lung cancer to be presented at ESMO
Read more
September 2016
2016 September, 28
Abstracts for European Society of Medical Oncology (ESMO) available online on Wednesday, 28th September 2016 12.00 (CET)
Read more
2016 September, 27
MPI granted patent on the Drug Response Predictor technology in China
Read more
2016 September, 20
MPIs spinout Oncology Venture signs partnership deal with Cadila Pharmaceuticals on LiPlaCis using MPI's DRP technology
Read more
2016 September, 14
MPIs PRP for precision medicine to be studied with Breast Cancer experts
Read more
2016 September, 09
MPIs spinout Oncology Venture incorporates 2X Oncology Inc. a Women's Cancer Company in the US
Read more
August 2016
2016 August, 31
CORRECTION: MPI - Interim Report First Half 2016
Read more
2016 August, 31
MPI - Interim Report First Half 2016
Read more
2016 August, 23
First DRP selected Breast Cancer Patient obtained reduction of tumor by LiPlaCis treatment
Read more
2016 August, 08
MPI - Cisplatin and APO010 abstracts selected by ESMO's Scientific Committee for poster presentation on its annual congress
Read more
July 2016
2016 July, 05
MPI and Oncology Venture enhances the collaboration by entering another agreement on DRP's
Read more
June 2016
2016 June, 21
MPI is listing on Nasdaq Stockholm First North. First day of trading is June 27th 2016
Read more
2016 June, 14
MPI - update on warrant program
Read more
2016 June, 09
MPI - Up-date on date of first day of trading on Nasdaq First North Stockholm
Read more
2016 June, 08
MPI giver meddelelse om storaktionærers ændringer af aktiebesiddelser jf. værdipapirhandelslovens §29.
Read more
2016 June, 02
Meet MPI at SACHS Immuno-Oncology BD&L, Chicago; ASCO, American Society of Clinical Oncology, Chicago; BIO in San Francisco
Read more
May 2016
2016 May, 31
MPI's DRP used in the first prospective study
Read more
2016 May, 27
Read & See All About it: "Fly fishing and treating cancer: same, same but different!" | Thomas Jensen | TEDx Bozeman
Read more
2016 May, 26
MPI - presents at Sedermeradagen in Gothenburg
Read more
2016 May, 12
MPI - Positive data on MPI's DRP for 5-FU published in PLOS ONE
Read more
2016 May, 03
MPI - Process Started Regarding Change of Marketplace
Read more
April 2016
2016 April, 27
MPI and Oncology Venture enters three new agreements on DRP's
Read more
2016 April, 20
Medical Prognosis Institute A/S - Forløb af ordinær generalforsamling

Read more
2016 April, 09
MPI - See MPI's CTO Thomas Jensen at TEDx Bozeman on April 9:th
Read more
2016 April, 06
Indkaldelse til Ordinær Generalforsamling
Read more
2016 April, 05
Interview with CEO Peter Buhl Jensen available
Read more
March 2016
2016 March, 18
MPI - Medical Prognosis Institute A/S publishes Annual Report 2015
Read more
2016 March, 16
MPI increases its capital by 2,000 shares as a result of warrant exercise
Read more
2016 March, 15
MPI will publish its Annual Report 2015 on March 18th
Read more
2016 March, 10
First patient included in APO010 immuno-oncology screening trial by MPI's spinout Oncology Venture
Read more
2016 March, 04
MPI's spinout Oncology Venture to present LiPlaCis dose-escalating PoC study at the AACR Annual Meeting 2016 in New Orleans
Read more
February 2016
2016 February, 24
MPI: Registration of capital increase completed
Read more
2016 February, 19
MPI raises DKK 8,686,575 in private placement at a price of 135
Read more
2016 February, 19
MPI's spinout OV has in-licensed LiPlaCis(TM):
Read more
2016 February, 18
MPI issues warrants
Read more
2016 February, 17
MPI - publishes positive results with DRP(TM) tool in gastroesophageal cancer
Read more
2016 February, 09
MPI - Summary of Extraordinary General Meeting
Read more
January 2016
2016 January, 28
CORRECTION: MPI is issued patent in Australia
Read more
2016 January, 28
MPI is issued patent in Australia
Read more
2016 January, 22
MPI - NOTICE OF EXTRAORDINARY GENERAL MEETING
Read more
December 2015
2015 December, 22
MPI participates at Biotech Showcase in San Francisco
Read more
2015 December, 07
MPI and Mundipharma EDO GmbH enters agreement of DRP(TM) for their anti cancer lead compound EDO-S101 in clinical trials
Read more
November 2015
2015 November, 27
MPI unblinds prospective study of LungChip prognosticator in early lung cancer
Read more
2015 November, 13
Labor & Economic Growth Minister is fighting for more IPOs_"It is a tax system problem"
Read more
2015 November, 08
DRP(TM) enables Irofulven clinical trial in prostate cancer
Read more
2015 November, 07
New academic drug screening platform for cancer treatment
Read more
2015 November, 06
Presentation of use of DRP(TM) in Top1 at AACR congress in Boston
Read more
September 2015
2015 September, 04
MPI - announces 3 abstracts on the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston
Read more
August 2015
2015 August, 31
Medical Prognosis Institute A/S - Interim Report First Half 2015
Read more
2015 August, 27
MPI will publish its half-year report for the first half year of 2015 on August 31st
Read more
June 2015
2015 June, 29
MPI's spinout, Oncology Venture announces oversubscription of 370 % of its emission prior to listing at the AktieTorget
Read more
2015 June, 09
Oncology Venture Sweden AB, a spinout from MPI IPOs at AktieTorget...

2015 June, 09
MPI and Nemucore announce strategic partnership...

2015 June, 05
Oncology Venture Sweden AB, a spinout from MPI announces its IPO at the Swedish AktieTorget
Read more
2015 June, 01
Medical Prognosis Institute and Nemucore Announce Strategic Partnership
Read more
May 2015
2015 May, 29
MPI's drug development arm Oncology Venture and Lantern Pharma announce partnership to advance Irofulven for metastatic prostate cancer
Read more
April 2015
2015 April, 28
Oncology Venture, MPI's drug development arm raises more than 6 million DKK from private investors
Read more
2015 April, 28
Oncology Venture, MPI's drug development arm raises more than 6 million DKK from private investors
Read more
March 2015
2015 March, 26
Medical Prognosis Institute A/S publishes Annual Report 2014
Read more
2015 March, 04
Oncology Venture, MPI's drug development arm and Lantern Pharma receive ICIP grant to advance Irofulven for metastatic prostate cancer
Read more
February 2015
2015 February, 26
MPI increases its capital by 2,000 shares as a result of warrant exercise
Read more
2015 February, 21
MPI's DPR technology predicts which lymphoma patients (DLBCL) respond to standard treatment (R-CHO(E)P) in a blind setting
Read more
November 2014
2014 November, 05
MPI and Alion Pharmaceuticals, Inc. establish partnership to develop Drug Response Predictors for ion channel inhibitors in Oncology
Read more
September 2014
2014 September, 17
MPI abstract published on the ESMO homepage shows that the MPI's genetic response profile can predict efficacy of adjuvant 5-FU in colon cancer
Read more
2014 September, 12
MPI is today publishing a prospectus in connection with an offering of a minimum of 44,330 and up to 104,064 new shares of DKK 1.00 nominal value each at a price of DKK 180.00 per new share
Read more
2014 September, 02
Medical Prognosis Institute A/S - Passing of Extraordinary General Meeting
Read more
August 2014
2014 August, 15
MPI - Notice of Extraordinary General Meeting in Medical Prognosis Institute A/S
Read more
2014 August, 12
Medical Prognosis Institute A/S - Interim Report First Half 2014
Read more
2014 August, 07
MPI advances the date for publication of its scheduled H1 report for 2014
Read more
July 2014
2014 July, 11
MPI's Lung Prognostic Chip study expanded with new gene test - publication of data consequently postponed to H1 2015
Read more
May 2014
2014 May, 27
MPI and LiPlasome present the phase 1 study with LiPlaCis at the ASCO congress Monday 2 in Chicago at 8am local time
Read more
2014 May, 23
MPI increases its capital by 67,774 shares as a result of the capital increase adopted on the annual general meeting held on 24 April 2014
Read more
April 2014
2014 April, 25
MPI increases its capital by 21,500 shares as a result of employee warrant exercise
Read more
2014 April, 24
Medical Prognosis Institute A/S - Passing of Annual General Meeting
Read more
2014 April, 09
Notice of Annual General Meeting in Medical Prognosis Institute A/S
Read more
2014 April, 03
MPI and TD2 join in strategic collaboration to provide drug developers a unique Multi Biomarker direct path to drug approval
Read more
March 2014
2014 March, 27
Medical Prognosis Institute A/S - Annual Report 2013
Read more
February 2014
2014 February, 05
MPI publishes data showing that MPI's product DRP may help to identify patients with tumors more likely to respond to fulvestrant
Read more
November 2013
2013 November, 04
MPI presents data on its Drug Response Predictor technology that can predict which indication will be approved by the FDA on the ADAPT Congress in Boston
Read more
October 2013
2013 October, 23
MPI receives 3.5 million DKK from The Danish Market Development Fund to develop the gene-test "Lung Prognosticator"
Read more
Show all

Events


March 2017
2017 March, 22
Listen to the Interview with Peter Buhl Jensen and Ulla hald Buhl
Read more
April 2016
2016 April, 13
The Digital Transformation in Pharma
Read more
March 2016
2016 March, 16
Sedermeradagen Lund 2016
Read more
June 2015
2015 June, 02
Foredrag på Aktionærmessen i Århus
Read more
May 2015
2015 May, 22
MPI will be participating at ASCO 2015 conference in Chicago from 28nd May to 3rd June 2015. Let's talk at he MPI booth # 20148.

Please contact:
Ulla Buhl
uhb@medical-prognosis.com
MOBILE: +45 2170 1049

2015 May, 05
Oncology Venture, MPI’s spin off company presented at Sedermeradagen in Göteborg.

http://www.sedermeradagen.se/tidigare-dagar/goteborg-5-maj-2015/
Read more
March 2015
2015 March, 04
MPI will attend the 9th International Partnering Conference 'Bio-Europe Spring 2015' March 9-11, in Paris, France.

Please contact
Claus Deichgräber, VP European Sales,
Cell: +45 2015 0605
Mail: cd@medical-prognosis.com

January 2015
2015 January, 30
MPI will attend 9th Swiss-Scandinavian Bio-Business Seminar

February 5, 2015
Zürich, Switzerland

Please contact
Claus Deichgräber, VP European Sales,
Cell: +45 2015 0605
Mail: cd@medical-prognosis.com

December 2014
2014 December, 23
MPI will attend the JPMorgan Conference

12-15 January 2015.

Please contact:
CEO Peter Buhl Jensen
pbj@medical-prognosis.com

September 2014
2014 September, 10
MPI præsenterer data på ESMO som viser at selskabet kan forudsige effekt af adjuverede behandling med 5-FU til tyktarmskræft
Read more
Show all

Stock price




PRICE:
SEK
CHANGE

Medical Prognosis Institute A/S

NASDAQ OMX First North:
MPI.ST

Data as of CEST

Financial calendar


H1 Report2016-08-31
Annual ReportTBA

Corporate Documents


Company descriptions
 NamePublished
Bolagsbeskrivning.pdf 2016-06-21
Virksomhedsbeskrivelse.pdf 2015-07-09
Project First - Company description - Final Version - PDF.pdf 2015-07-09
Investor Relation Policy
 NamePublished
Medical Prognosis Institute - Investor Relations policy June 2016.pdf 2016-06-08
Corporate Responsibility
 NamePublished
Corporate Responsibility.pdf 2015-07-09
Insider List
 NamePublished
Insider List 20160614.pdf 2016-06-14
Our Certified Advisor:

 

Sedermera Fondkommission 

Norra Vallgatan 64

210 22 Malmö, Sweden

+46 (0)431-47 17 00
ca@sedermera.se
Fax: +46 (0)431-47 17 21